The current Covid vaccines are designed to trigger an antibody response to the SARS-CoV-2 spike protein, which is vulnerable to mutations that could make the vaccine less effective over time. Focu
Pennsylvania State University researchers in the US partnered with Evaxion Biotech on a study that was the first to demonstrate the effectiveness of an AI-generated vaccine in a live viral challenge model.